{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:44:26Z","timestamp":1785300266122,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.metabol.2006.07.025","type":"journal-article","created":{"date-parts":[[2006,12,3]],"date-time":"2006-12-03T07:12:21Z","timestamp":1165129941000},"page":"1645-1652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy"],"prefix":"10.1016","volume":"55","author":[{"given":"Sachiko","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohzo","family":"Takebayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2006.07.025_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/01.ATV.0000048856.22331.50","article-title":"Coronary artery disease. Association of hypoadeponectinemia with coronary artery disease in men","volume":"23","author":"Kumada","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2006.07.025_bib2","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/jama.291.14.1730","article-title":"Plasma adiponectin levels and risk of myocardial infarction in men","volume":"291","author":"Pischon","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2006.07.025_bib3","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nm0796-800","article-title":"Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity","volume":"2","author":"Shimomura","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2006.07.025_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004872-200018110-00011","article-title":"The contribution of skeletal muscular tumor necrosis factor \u03b1 to insulin resistance and hypertension in fructose-fed rats","volume":"18","author":"Togashi","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2006.07.025_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/jama.283.2.221","article-title":"Hyperinsulinemia, hyperglycemia and impaired hemostasis. The Framingham Offspring study","volume":"283","author":"Meigs","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2006.07.025_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(02)09335-2","article-title":"Adiponectin and development of type 2 diabetes in the Pima Indian population","volume":"360","author":"Lindsay","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2006.07.025_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nm724","article-title":"Diet-induced insulin resistance in mice lacking adiponectin\/ACRP30","volume":"8","author":"Maeda","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2006.07.025_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cccn.2004.02.020","article-title":"Adiponectin and atherosclerotic disease","volume":"344","author":"Shimada","year":"2004","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2006.07.025_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.1097243","article-title":"Visfatin: a protein secreted by visceral fat that mimics the effects of insulin","author":"Fukuhara","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.metabol.2006.07.025_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","article-title":"Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis","volume":"37","author":"Dzau","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2006.07.025_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1046\/j.1523-1755.61.s80.28.x","article-title":"Kidney and hypertension","volume":"80","author":"Adamczak","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2006.07.025_bib12","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1172\/JCI119752","article-title":"Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin\/angiotensin II crosstalk","volume":"100","author":"Folli","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2006.07.025_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1357-2725(02)00311-4","article-title":"The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?","volume":"35","author":"Engeli","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.metabol.2006.07.025_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.HYP.0000078490.59735.6E","article-title":"Blockade of the renin-angiotensin system increase adiponectin concentrations in patients with essential hypertension","volume":"42","author":"Furuhashi","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2006.07.025_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.thromres.2005.04.008","article-title":"Effect of valsartan on monocyte\/endothelial activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus","volume":"117","author":"Nomura","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.metabol.2006.07.025_bib16","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2006.07.025_bib17","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2006.07.025_bib18","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1210\/me.2005-0089","article-title":"The mineralocorticoid receptor: a journey exploring its diversity and specificity of action","volume":"19","author":"Pascual-Le Tallec","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.metabol.2006.07.025_bib19","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2006.07.025_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2006.07.025_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1210\/jc.2005-1632","article-title":"Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin converting enzyme inhibitor therapy","volume":"91","author":"Jawa","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2006.07.025_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2006.07.025_bib23","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa022600","article-title":"Soluble CD 40 ligand in acute coronary syndrome","volume":"348","author":"Heeschen","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2006.07.025_bib24","first-page":"S66","article-title":"Diabetic nephropathy","volume":"22","author":"American Diabetes Association","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2006.07.025_bib25","series-title":"Current diagnosis and management of chorioretinal disease","first-page":"179","article-title":"Natural evolution","author":"Davis","year":"1974"},{"key":"10.1016\/j.metabol.2006.07.025_bib26","unstructured":"Diabetes Treatment Guideline 2004-2005 edited by Japan Diabetes Society. Tokyo, Japan, Bunkodo (in Japanese)."},{"key":"10.1016\/j.metabol.2006.07.025_bib27","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/diacare.27.10.2392","article-title":"Adiponectin concentration in sera from patients with type 2 diabetes are negatively associated with sympathovagal balance as evaluated by power spectral analysis of heart variation","volume":"27","author":"Wakabayashi","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2006.07.025_bib28","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1161\/01.ATV.20.6.1595","article-title":"Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients","volume":"20","author":"Hotta","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2006.07.025_bib29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1046\/j.1523-1755.2000.00277.x","article-title":"Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo","volume":"9","author":"Brown","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2006.07.025_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000066348","article-title":"Effect of spironolactone on impaired fibrinolysis of hypertensive patients","volume":"25","author":"Yalcin","year":"2002","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.metabol.2006.07.025_bib31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1464-5491.1991.tb01536.x","article-title":"Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes","volume":"8","author":"Walmsely","year":"1991","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2006.07.025_bib32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/diabetes.51.4.1131","article-title":"Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The insulin resistance atherosclerosis study","author":"Festa","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2006.07.025_bib33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0735-1097(00)00796-8","article-title":"Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure","volume":"36","author":"Tsutamoto","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2006.07.025_bib34","first-page":"341","article-title":"Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure","volume":"9","author":"Feola","year":"2003","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.metabol.2006.07.025_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049506002836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049506002836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:17:42Z","timestamp":1758424662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049506002836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0026049506002836"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2006.07.025","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2006.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}